Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204576 | 0.83 | TSHR (0.44) | HTTKAT2BBRD9SMN1; SMN2NPC1 | |
| SCHEMBL966692 | 0.83 | KDM4E (0.41) | HTTKAT2BBRD9SMN1; SMN2NPC1 | |
| SCHEMBL2015049 | 0.83 | MAPK1 (0.45) | HTTKAT2BBRD9SMN1; SMN2NPC1 | |
| SCHEMBL3050197 | 0.81 | RAB9A (0.49) | HTTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL4023990 | 0.79 | HTT (0.35) | HTTKAT2BBRD9SMN1; SMN2NPC1 | |
| SCHEMBL27714949 | 0.79 | PROKR1 (0.39) | HTTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL9204354 | 0.79 | CYP1A2 (0.44) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL939312 | 0.79 | MAPT (0.41) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL20524592 | 0.76 | HSD11B1 (0.47) | HTTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL11893138 | 0.75 | MGLL (0.36) | HTTSMN1; SMN2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-10131640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2018-11-20 | — | — | US | disclosed |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2016-05-19 | — | — | US | disclosed |
| US-9238640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2016-01-19 | — | — | US | disclosed |
| EP-1940792-B1 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES AS INHIBITORS OF PIM-1 AND/OR PIM-3 | EXELIXIS INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004072034-A1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-26 | — | — | WO | disclosed |
| US-20040167166-A1 | Amino-piperidine derivatives | HOFFMANN-LA ROCHE INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| EP-0707000-A1 | ALDOXIME DERIVATIVE AND AGROHORTICULTURAL BACTERICIDE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1996-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | HTT 4509/4885KAT2B 3395/4885BRD9 1477/4885 |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | HTT 4528/4885KAT2B 3220/4885BRD9 1269/4885 |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | HTT 663/4885KAT2B 182/4885BRD9 52/4885 |
| US-10882828-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | HTT 4509/4885KAT2B 3395/4885BRD9 1477/4885 |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | HTT 1717/4885KAT2B 2639/4885BRD9 1219/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | HTT 1392/4885KAT2B 3113/4885BRD9 1502/4885 |
| US-20040167166-A1 | Amino-piperidine derivatives | OPRL1, GRIA1, GRIN1 | HTT 564/4885KAT2B 1138/4885BRD9 3855/4885 |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | HTT 4509/4885KAT2B 3395/4885BRD9 1477/4885 |
| US-10131640-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | HTT 4509/4885KAT2B 3395/4885BRD9 1477/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | HTT 1392/4885KAT2B 3113/4885BRD9 1502/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | HTT 2723/4885KAT2B 3005/4885BRD9 2011/4885 |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | HTT 4528/4885KAT2B 3220/4885BRD9 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.